Suzhou Molarray Co., Ltd.

Suzhou Molarray Co., Ltd. is a high-tech enterprise specializing in molecular diagnosis, genetic testing technology, and microbial testing technology. Established in 2010, Molarray operates from a spacious 30,000 square meter production workshop located in Biobay, a national Biomedical Industrial Park in Suzhou, China. In addition to its main facility, Molarray has expanded its operations by establishing a R&D center in Canada and a marketing center in Shanghai in 2016, enabling seamless integration of research, production, and sales. With a focus on gene technology, Molarray leverages its technical expertise to explore various application fields and develop innovative products. Over the course of 20 years, Molarray has made relentless efforts and successfully built a comprehensive portfolio of products and technologies. The primary offerings include nucleic acid extraction and purification instruments, PCR instrument series, workstations (including dispensing and sample processing systems, nucleic acid extraction automation workstations, automated PCR workstations, and integrated nucleic acid analyzers), and component series. Molarray has amassed significant experience in research and development across multiple disciplines, including automation control, image processing, optical detection, microscopy, liquid circuits, electronic applications, and software. With over 40 global patents and around 20 software copyrights, Molarray has demonstrated its commitment to innovation. Molarray also maintains the essential production licenses, sales licenses, and business licenses for all its medical devices. Furthermore, the company has successfully obtained ISO9001 and ISO13485 quality management system certifications, underscoring its dedication to maintaining high standards of product quality and safety. Amid the fight against the COVID-19 pandemic, Molarray's PCR machines are used to help detect and identify the virus. The company secured a $120.00K Funding Round investment on 13 October 2017, with BMC as the investor.